New gene therapy aims to halt vision loss in rare eye disease
Disease control
Recruiting now
This early-stage trial tests a gene therapy called VG801 for people with Stargardt disease, an inherited condition that causes progressive vision loss. The study will enroll 15 participants aged 6 and older who have confirmed ABCA4 gene mutations and poor vision in one eye. The g…
Phase: PHASE1, PHASE2 • Sponsor: VeonGen Therapeutics GmbH • Aim: Disease control
Last updated May 13, 2026 16:01 UTC